Q3 2025 Strata Critical Medical Inc Earnings Call Transcript

Nov 10, 2025 / 01:00 PM GMT

Release Date Price: $4.85 (+9.48%)

Transcript 10-Q8-K

Key Points

Positve

Strata Critical Medical Inc (SRTA) reported a 29% year-over-year revenue growth, excluding Keystone, surpassing expectations for mid-teens growth.
The company achieved an 80% year-over-year growth in segment adjusted EBITDA, excluding Keystone, driven by volume and improvements in aircraft performance.
The integration of Keystone and the launch of Strata's new clinical services division have been successful, enhancing their organ recovery platform.
Strata's go-to-market strategy focuses on co-locating resources closer to customers, reducing costs and improving service delivery.
The company raised its 2025 revenue guidance to $185 to $195 million, reflecting strong demand and performance.

Negative

The Keystone acquisition led to a complex accounting treatment, resulting in a negative operating cash flow for the quarter.
There was a significant decline in Jovi's stock price, affecting the cash proceeds from the monetization of shares.
The company experienced a sequential seasonal decline in industry-wide transplant volumes, impacting overall growth.
Strata had to book a legal provision related to ongoing litigation concerning a past transaction.
Despite improvements, the company still faces challenges with heavy maintenance schedules impacting fleet margins.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SRTA.OQ - Strata Critical Medical Inc
Q3 2025 Strata Critical Medical Inc Earnings Call
Nov 10, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning ladies and gentlemen, and welcome to Strata Critical Medical fiscal 3rd quarter 2025 earnings release conference call. At the time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer sessions and instructions will follow at that time. As a reminder, this call is being recorded.

I would now like to turn a conference call over to Matt Freider, Vice President of Finance and Investor relations and CFO of Strata, Keystone Perfusion subsidiary. Matt, you may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.